Charles River Laboratories (NYSE: CRL) reported Q4 EPS of $2.39, $0.04 better than the analyst estimate of $2.35. Revenue for the quarter came in at $994.2 million versus the consensus estimate of $987.2 million.

GUIDANCE:

Charles River Laboratories sees FY2026 EPS of $10.70-$11.20, versus the consensus of $10.89.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.